Who is the sponsor?
Who are the patients?
Male or female patients over the age of fifty-five with Dry AMD The participating doctor will evaluate the patient to determine his/her eligibility into the study in accordance with the Study Inclusion and Exclusion Criteria.
How long are the eligible patients enrollment?
Assessments for treatment will be made every 3 months for a period of 24 months.
When did participation agreement start at our site?
What is the enrollment goal for the sponsor?
Is the enrollment still open?
No. Is still ongoing at this time.
What is this study investigating?
This is a Phase II randomized, double-masked, does ranging, multi-center study comparing OT-551 with vehicle placebo for the treatment of geographic atrophy (GA) progression in subjects with GA associated with age-related macular degeneration (AMD) with the following objectives: To determine if treatment with OT-551 reduces the risk of vision loss and areas of GA progression. To asses the safety profile of OT-551 across treatments.
How is the treatment administered?
Assigned study drug is administered as an eye drop to be used four times daily with an application of two drops each time in the study eye only.